开发并验证一种用于补充非小细胞肺癌分期的全新代谢肿瘤体积风险分层系统
该研究基于935例FDG高摄取的非小细胞肺癌(NSCLC)患者,回顾性分为建模队列与验证队列,利用全身代谢肿瘤体积(MTVwb)四分位数切点(10.0、53.4、155.0 mL)建立风险分层系统。生存分析显示较低MTVwb风险分层与更好总生存相关(所有p<0.01),且独立于TNM分期及其他临床预后因素;该系统与TNM分期的判别力无显著差异。MTVwb风险分层与TNM分期或亚分期的错分率在建模队列为45.1%、验证队列为50.3%。
要点
- MTVwb风险分层较低与更好总生存相关(所有p<0.01),独立于TNM分期及其他临床预后因素。
- MTVwb风险分层系统与TNM分期的判别力(Gönen-Heller一致性指数)在两个队列中均无显著差异。
- MTVwb风险分层与TNM分期或亚分期的错分率在建模队列为45.1%、验证队列为50.3%。
核心结论
- 本研究开发并验证了一种全新的MTVwb风险分层系统,其在NSCLC中具有独立于TNM分期及其他临床预后因素的预后价值,提示可用于进一步NSCLC治疗前评估及细化个体化治疗决策。
研究设计与样本
- 经IRB批准的回顾性研究,纳入935例FDG高摄取肿瘤的NSCLC患者,根据所用PET/CT扫描仪类型分为建模队列与验证队列。
- 另通过将患者人群分为两个随机队列进行敏感性分析。
- 采用Cox回归和Kaplan-Meier生存分析评估MTVwb风险分层系统的预后价值。
主要发现
- 建模队列MTVwb四分位数间切点值(10.0、53.4和155.0 mL)应用于建模队列和验证队列以确定每例患者的MTVwb风险分层。
- 生存分析显示较低MTVwb风险分层与更好总生存相关(所有p<0.01),独立于TNM分期及其他临床预后因素。
- 以Gönen和Heller一致性指数衡量,MTVwb风险分层系统的判别力在两个队列中与TNM分期均无显著差异。
- MTVwb风险分层的预后价值在两个随机队列中均稳健。
- MTVwb风险分层与TNM分期或亚分期的错分率在建模队列为45.1%,在验证队列为50.3%。
关键数值与推荐
- MTVwb四分位数间切点值为10.0、53.4和155.0 mL(建模队列)。
- 较低MTVwb风险分层与更好总生存相关,所有p<0.01。
- MTVwb风险分层与TNM分期或亚分期的错分率:建模队列45.1%,验证队列50.3%。
临床怎么用
- 原文结论提示该MTVwb风险分层系统可用于进一步NSCLC治疗前评估及细化个体化治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that whole-body metabolic tumor volume (MTVwb) could be used to supplement non-small cell lung cancer (NSCLC) staging due to its independent prognostic value. The goal of this study was to develop and validate a novel MTVwb risk stratification system to supplement NSCLC staging. METHODS: We performed an IRB-approved retrospective review of 935 patients with NSCLC and FDG-avid tumor divided into modeling and validation cohorts based on the type of PET/CT scanner used for imaging. In addition, sensitivity analysis was conducted by dividing the patient population into two randomized cohorts. Cox regression and Kaplan-Meier survival analyses were performed to determine the prognostic value of the MTVwb risk stratification system. RESULTS: The cut-off values (10.0, 53.4 and 155.0 mL) between the MTVwb quartiles of the modeling cohort were applied to both the modeling and validation cohorts to determine each patient's MTVwb risk stratum. The survival analyses showed that a lower MTVwb risk stratum was associated with better overall survival (all p < 0.01), independent of TNM stage together with other clinical prognostic factors, and the discriminatory power of the MTVwb risk stratification system, as measured by Gönen and Heller's concordance index, was not significantly different from that of TNM stage in both cohorts. Also, the prognostic value of the MTVwb risk stratum was robust in the two randomized cohorts. The discordance rate between the MTVwb risk stratum and TNM stage or substage was 45.1% in the modeling cohort and 50.3% in the validation cohort. CONCLUSION: This study developed and validated a novel MTVwb risk stratification system, which has prognostic value independent of the TNM stage and other clinical prognostic factors in NSCLC, suggesting that it could be used for further NSCLC pretreatment assessment and for refining treatment decisions in individual patients.
引用
- Pu Y, Zhang JX, Liu H, et al. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018. PMID: 29882161. doi:10.1007/s00259-018-4059-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。